OnKure Therapeutics (NASDAQ:OKUR) used a scientific webcast to outline its strategy for developing mutant-selective PI3Kα inhibitors, emphasizing allosteric inhibition as a potential way to improve efficacy and tolerability in cancer and vascular anomalies.
Nick Saccomano, president and chief execu
OnKure Therapeutics (OKUR) reported Q2 2025 EPS of -$1.14, beating estimates, with no revenue. Stock rose 1.5% after hours. Clinical progress on OKI-219 cancer drug remains on track for Q4 2025 data.
OnKure Therapeutics has garnered attention following its merger with Reneo Pharmaceuticals and a $65 million private placement. Oppenheimer initiated coverage with an Outperform rating, highlighting the potential of OKI-219 in targeting breast cancer mutations.
